Drug Trial Radar · NCT04366648
Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor
Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
May 4, 2018
Primary completion
Mar 31, 2021
Study completion Mar 31, 2021
Sponsor
- Lead sponsor
- JenKem Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety and tolerability of injectable PEG-Irinotecan in patients with malignant solid tumors
Conditions
- Solid Tumor
Interventions
JK-1201IDrug
malignant solid tumor that has been confirmed by histopathology and/or cytology
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary outcome 1Time frame: 21 days
- Primary outcome 2Time frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The fifth medical center of PLA general hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.